Monday, November 9, 2026

USD/EUR Bullish By 2% In The Last 21 Sessions

ViaNews Editorial Team

September 29, 2023

USD/EUR Bullish By 2% In The Last 21 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 2.54% for the last 21 sessions. At 15:06 EST on Friday, 29 September, USD/EUR (USDEUR) is $0.95.

USD/EUR's yearly highs and lows, it's 6.596% up from its 52-week low and 8.903% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was 0.13%, 0.08%, and 0.31%, respectively.

USD/EUR's highest amplitude of average volatility was 0.37% (last week), 0.34% (last month), and 0.31% (last quarter), respectively.

News about

  • Usd/jpy price analysis: pullbacks from 11-month high near 149.50. According to FXStreet on Thursday, 28 September, "The current upward momentum in USD/JPY appears to have a potential bullish bias, given that the 14-day Relative Strength Index (RSI) remains above the 50 level. ", "If there's a strong breakthrough above the level, it could serve as an encouragement for USD/JPY bulls to explore higher levels, potentially targeting the area around the October high at 151.94."
  • Usd/jpy climbs to 149.50 amid the stronger usd, bulls turn cautious amid intervention fears. According to FXStreet on Wednesday, 27 September, "Traders turn cautious to place bullish bets on the USD/JPY pair since the 150.00 mark would be the threshold at which Japanese authorities would take action to address the Japanese Yen's depreciation. "
  • Usd/jpy oscillates in a range around 149.00 mark, just below the YTD peak set on Tuesday. According to FXStreet on Wednesday, 27 September, "In contrast, the Federal Reserve (Fed) signalled the possibility of at least one more rate hike by the end of this year, which allows the US Dollar (USD) to stand tall near the YTD peak and acts as a tailwind for the USD/JPY pair.", "The USD/JPY pair struggles to gain any meaningful traction on Wednesday and oscillates in a narrow trading band through the Asian session. "
  • Usd/jpy eyes 150.00 amid hawkish fed and dovish boj, but intervention threats loom. According to FXStreet on Wednesday, 27 September, "Nevertheless, if USD/JPY corrects lower, first support would emerge at the Tenkan-Sen at 148.39, followed by the September 7 daily high at 147.87, and the Kijun-Sen at 146.95."
  • Usd/jpy technical analysis: fears over currency decline - 27 September 2023. According to DailyForex on Wednesday, 27 September, "The currency pair the US dollar against the Japanese yen USD/JPY quickly returned to its strong upward path with long gains. ", "Expectations of the US dollar against the Japanese yen today:There is no change in my technical point of view for the USD/JPY currency pair."

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Cycle: Data Readouts, FDA Decisions and Capital-Allocation Shifts
From late October to January, mid-cap biotechs move through a dense run of events: ESMO and AHA/AASLD data presentations, Q3 earnings, and FDA PDUFA dates for ivonescimab (Nov 14) and lorundrostat (Dec 22). Alongside the regulatory news, companies are changing how they allocate capital: one lowered FY2026 R&D and SG&A guidance and pushed milestones into 2027, one authorized a $400M buyback, and one scheduled a delisting vote (EGM Nov 19, application Jan 25). Value is concentrating in a few binary regulatory and Phase 3 outcomes (Maritime-1 and ECLIPSE 2/3 readouts around Q1 2027), so sentiment is mixed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,558 source documents archived
Query this data → isubstrate.com